Correlation of effective hepatic blood flow with liver pathology in patients with hepatitis B virus
Open Access
- 1 December 2021
- journal article
- research article
- Published by KEAI Publishing in Liver Research
- Vol. 5 (4) , 243-250
Abstract
Effective hepatic blood flow (EHBF) decreases with liver disease progression, and identifying liver pathology is critical for patients with liver disease. This study was designed to elucidate the correlation between EHBF and liver pathology and explore the potential of EHBF for predicting the degree of liver pathology. In this study, 207 patients with hepatitis B virus (HBV) who underwent liver biopsy and indocyanine green (ICG) clearance tests were enrolled. EHBF was measured using the ICG clearance test, and liver tissue was histologically analyzed to determine the pathological stage according to the Scheuer scoring system. Demographic data, biochemical indexes, and FibroScan data were collected for statistical analysis. EHBF levels decreased as the liver histological stages of inflammation and fibrosis increased (P < 0.01). EHBF was significantly negatively associated with the levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, aspartate aminotransferase-to-platelet ratio index, fibrosis index based on the four factors, and liver stiffness measurement (P < 0.05). The EHBF levels of patients without liver inflammation (G0) were significantly higher than those of patients with liver inflammation (G1–4) (P < 0.001). The area under the receiver operating characteristic curve (AUROC) value for discriminating patients without liver inflammation was 0.827, and the optimal cutoff value was 0.936 L/min. The EHBF levels of patients with severe liver inflammation (G4) were significantly lower than those of patients with G0–3 liver inflammation (P < 0.001). The AUROC value for discriminating patients with severe liver inflammation was 0.792, and the optimal cutoff value was 0.552 L/min. The EHBF levels of patients without liver fibrosis (S0) were significantly higher than those of patients with liver fibrosis (S1–4) (P < 0.001). The AUROC value for discriminating patients without liver fibrosis was 0.633, and the optimal cutoff value was 1.173 L/min. The EHBF levels of patients with liver cirrhosis (S4) were significantly lower than those of patients with S0–3 liver fibrosis (P < 0.001). The AUROC value for discriminating patients with liver cirrhosis (S4) was 0.630, and the optimal cutoff value was 0.562 L/min. EHBF levels and liver pathology are significantly correlated. EHBF could effectively reflect liver inflammation and fibrosis in patients infected with HBV, especially for patients without liver inflammation or liver fibrosis.Keywords
Funding Information
- Guangzhou Municipal Science and Technology Program key projects (202002030044)
This publication has 28 references indexed in Scilit:
- Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C VirusInternational Journal of Molecular Sciences, 2016
- Association Between MC-2 Peptide and Hepatic Perfusion and Liver Injury Following Resuscitated Hemorrhagic Shock.JAMA Surgery, 2016
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosisJournal of Hepatology, 2015
- Correlation between hepatic blood flow and liver function in alcoholic liver cirrhosisWorld Journal of Gastroenterology, 2014
- Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markersHepatology, 2013
- Preservation of hepatic blood flow by direct peritoneal resuscitation improves survival and prevents hepatic inflammation following hemorrhagic shockAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Hepatic Blood Flow Plays an Important Role in Ischemia-Reperfusion Injury†Liver Transplantation, 2011
- Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease†Hepatology, 2008
- The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999-2002American Journal of Gastroenterology, 2006
- Hepatic Perfusion Parameters in Chronic Liver DiseaseAmerican Journal of Roentgenology, 2001